MetaCap

Editas Medicine Inc. Company Profile

NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.64-0.07 (-4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Editas Medicine at a glance

Editas Medicine Inc. (NASDAQ: EDIT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Cambridge, MA. Editas Medicine is led by Dr. Gilmore O'Neill M.D. and employs about 87 people. The company's shares have traded publicly since 2016.

At a market capitalization of $253.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001650664, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Editas Medicine do?

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Editas Medicine Inc.
Ticker
NASDAQ: EDIT
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Gilmore O'Neill M.D.
Employees
87
Headquarters
11 Hurley Street, Cambridge, MA, United States
Phone
617 401 9000
IPO year
2016
Market cap
$253.12M
SEC CIK
0001650664
Latest annual report
10-K · Mar 9, 2026

Companies similar to Editas Medicine

EDIT peer companies
CompanyPrice% ChgMarket capCompare
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs EDIT
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs EDIT
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs EDIT
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs EDIT
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs EDIT
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs EDIT
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs EDIT
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs EDIT

Related